February 22, 2022
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022
February 3, 2022
Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
January 11, 2022
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference
November 24, 2021
Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
November 10, 2021
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
November 8, 2021
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
November 3, 2021
Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
September 30, 2021
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 15, 2021
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit